Kirin Holdings (2503) FY2026 Q2 Earnings Report

Quick View

Executive Summary

This earnings period delivered a substantial increase in profit relative to revenue growth, with operating leverage becoming evident through improved gross margins and restrained SG&A expenses. Revenue was ¥1兆2,178.8B (+7.2% YoY), Operating Income was ¥1,290.4B (+87.8%), and consolidated Net Income was ¥1,161.0B (+92.0%). The Operating Margin improved from 6.0% in the previous year to 10.6%, driven by the Pharmaceuticals segment’s higher profitability and increased revenue and profit in Alcoholic Beverages. Revenue progress against the Full-Year forecast was 49.1%, a standard level, while profit progress was ahead of expectations, suggesting that the forecast may assume normalization of profit margins in the second half.

Factors Affecting Performance

【Revenue】Revenue increased 7.2% YoY to ¥1兆2,178.8B. The Pharmaceuticals segment posted the highest growth at +14.3%, followed by Non-Alcoholic Beverages at +8.5%, Alcoholic Beverages at +5.1%, and Health Science at +1.3%. Growth in Pharmaceuticals and Non-Alcoholic Beverages led top-line expansion.

【Profit and Loss】Operating Income increased 87.8% YoY to ¥1,290.4B. The gross margin improved to 48.7% (46.9% in the previous year), while the SG&A ratio declined to 38.1% (38.6% in the previous year), allowing operating leverage to take effect. By segment, Operating Income in Pharmaceuticals expanded sharply by 80.7%, with an outstanding profit margin of 23.0%; Alcoholic Beverages also increased 16.8%, improving its profit margin to 12.0%. Profit Before Tax was ¥1,508.5B, with equity-method income of ¥203.1B and a financial surplus of ¥15.1B contributing to the increase. This was a high-quality earnings increase, characterized by both revenue and profit growth, with profit growth significantly outpacing revenue growth.

Segment Analysis

The Pharmaceuticals segment generated revenue of ¥2,634.9B (+14.3%) and Operating Income of ¥605.4B (+80.7%), with a profit margin of 23.0%, making it the primary contributor to the increase in consolidated profit. Alcoholic Beverages generated revenue of ¥5,178.4B (the largest revenue composition), Operating Income of ¥620.9B (+16.8%), and a profit margin of 12.0%. Non-Alcoholic Beverages generated revenue of ¥2,948.8B (+8.5%) and Operating Income of ¥309.6B (+4.8%), indicating somewhat slower profit growth relative to revenue growth. Health Science generated revenue of ¥1,288.4B (+1.3%) and Operating Income of ¥104.0B (+20.8%), representing a significant profit improvement relative to its revenue growth rate. Higher profitability in Pharmaceuticals was the primary driver of the improvement in the consolidated Operating Margin.

Key Financial Indicators

【Profitability】The Operating Margin was 10.6% (6.0% in the previous year), while the consolidated Net Profit Margin was 9.5%, supported by the high gross margin of 48.7% and the decline in the SG&A ratio to 38.1%. 【Cash Flow Quality】Operating Cash Flow (OCF) was ¥1,373.5B, exceeding consolidated Net Income of ¥1,161.0B, indicating sound cash backing for earnings. 【Investment Efficiency】ROE (annualized) of 13.8% represents a favorable level for both asset efficiency and capital efficiency. 【Financial Soundness】The Equity Ratio was 40.0%, while EBIT-based interest coverage was approximately 11.7x against financial expenses of ¥110.4B, indicating a stable financial foundation. Meanwhile, goodwill of ¥5,495.7B accounted for 32.7% of net assets, indicating a relatively high degree of dependence on intangible assets.

Cash Flow Analysis

Operating Cash Flow was ¥1,373.5B, a substantial increase of 104.2% YoY, demonstrating cash-generation capacity exceeding consolidated Net Income of ¥1,161.0B. In terms of working capital, a decrease in trade receivables contributed a cash inflow of ¥1,149.7B, while an increase in inventories of ¥91.1B and a decrease in trade payables of ¥310.2B were sources of cash outflow. Investing Cash Flow was an inflow of ¥536.6B, although ¥652.5B was allocated to capital expenditures, indicating that the composition of investing activities also included cash inflows other than capital expenditures. Financing Cash Flow was an outflow of ¥1,624.7B, primarily due to dividend payments of ¥299.8B and share repurchases of ¥345.5B. Free Cash Flow (Operating Cash Flow + Investing Cash Flow) was ¥1,910.1B, a level sufficient to fund both shareholder returns and capital expenditures.

Earnings Quality

The 87.8% increase in Operating Income was supported by recurring factors—improved gross margins and restrained SG&A expenses—and dependence on non-recurring gains and losses was limited. Profit Before Tax of ¥1,508.5B exceeded Operating Income of ¥1,290.4B by ¥218.1B, attributable to equity-method income of ¥203.1B and a financial surplus of ¥15.1B, indicating that the performance of affiliated companies contributed to a portion of earnings. Operating Cash Flow exceeded consolidated Net Income, and accruals were small, suggesting favorable earnings quality. Nevertheless, the magnitude of changes in other operating income and expenses was significant, and the progress of these items in the second half should be monitored to assess the repeatability of the improvement in Operating Margin.

Earnings Forecasts and Guidance

The Full-Year forecast is revenue of ¥2兆4,800B and Net Income of ¥1,940B (+8.4% YoY), and the earnings forecast was revised during the current quarter. First-half revenue of ¥1兆2,178.8B represented progress of 49.1%, a standard level, while Net Income of ¥1,161.0B represented progress of 59.8%, ahead of expectations. Relative to the strong profit growth in the first half, the second half may incorporate comparatively conservative assumptions. The annual dividend forecast is ¥76.00 per share, with no revision to the dividend forecast.

Shareholder Returns

The interim dividend for the first half was ¥38.00 per share, an increase from ¥37.00 in the same period of the previous year. The Full-Year dividend forecast is ¥76.00, with no revision to the dividend forecast. Dividend payments amounted to ¥299.8B, while share repurchases of ¥345.5B were also conducted, resulting in total shareholder returns of ¥645.3B. The Payout Ratio based solely on dividends must be distinguished from the Total Return Ratio including share repurchases; Operating Cash Flow of ¥1,373.5B, the source of funds for shareholder returns, exceeded total shareholder returns.

Risk Factors

1. Raw Material and Foreign Exchange Risk: While the high gross margin of 48.7% indicates pricing power, delays in passing through costs could pressure profit margins during periods of volatility in raw material, packaging material, and energy prices, as well as foreign exchange rates.

2. Goodwill and Intangible Asset Impairment Risk: Goodwill of ¥5,495.7B accounted for 32.7% of net assets, while intangible assets accounted for 20.3% of total assets. If the profitability of acquired businesses declines, impairment losses under IFRS could have a temporary impact on profit and Equity.

3. Performance Volatility of Equity-Method Affiliates: Equity-method income was ¥203.1B, accounting for 13.5% of Profit Before Tax. Changes in the performance and business environment of affiliated companies could affect consolidated earnings.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (Food and Beverage)

Profitability and Return

The Company’s Operating Margin of 10.6% is considered favorable, although comparable data within the industry is limited.

Growth and Capital Efficiency

A revenue growth rate of 7.2% indicates a trend of revenue growth.

※Source: Compiled by the Company

Key Earnings Highlights

1. The Operating Margin improved substantially from 6.0% in the previous year to 10.6%, with higher profitability in the Pharmaceuticals segment, an increase in the gross margin, and a decline in the SG&A ratio indicating structural improvement through operating leverage.

2. Operating Cash Flow remained above Net Income, indicating sound cash backing for first-half earnings. Meanwhile, goodwill and intangible assets account for a composition ratio close to more than half of total assets, making the maintenance of profitability in acquired assets an important valuation factor going forward.

3. The progress rate of Full-Year Net Income exceeds that of revenue, making it important to continue monitoring the assumptions for second-half profit and the repeatability of other operating income and expenses through subsequent earnings data.

Theoretical Share Price (Reference Value)

Sensitivity: 1,862円–1,972円 at ±1% for the Cost of Equity, and 1,911円–1,923円 at ±0.1 for ω.

Notes:

• Since the progress of Net Income against the Full-Year forecast (64%) exceeds the standard level (50%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies ahead of forecast progress tend to exceed their forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Goodwill represents a high proportion of net assets, and the assumptions would change significantly if impairment occurs.
• Net assets as of the quarter-end are used (there is a timing gap relative to the Full-Year forecast).

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated solely from publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific stock. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---